Avidity Biosciences Stock Today
| RNA Stock | USD 43.33 0.47 1.07% |
Performance2 of 100
| Odds Of DistressLess than 45
|
Avidity Biosciences is trading at 43.33 as of the 28th of November 2024, a 1.07 percent decrease since the beginning of the trading day. The stock's open price was 43.8. Avidity Biosciences has 45 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Equity ratings for Avidity Biosciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of December 2022 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of June 2013 | Category Healthcare | Classification Health Care |
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. Avidity Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 119.31 M outstanding shares of which 14.66 M shares are at this time shorted by investors with about 13.94 days to cover. More on Avidity Biosciences
Moving together with Avidity Stock
Moving against Avidity Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Avidity Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Sarah Boyce | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAvidity Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Avidity Biosciences' financial leverage. It provides some insight into what part of Avidity Biosciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Avidity Biosciences (RNA) is traded on NASDAQ Exchange in USA. It is located in 10578 Science Center Drive, San Diego, CA, United States, 92121 and employs 253 people. Avidity Biosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a total capitalization of 5.23 B. Avidity Biosciences runs under Biotechnology sector within Health Care industry. The entity has 119.31 M outstanding shares of which 14.66 M shares are at this time shorted by investors with about 13.94 days to cover.
Avidity Biosciences has about 398.22 M in cash with (119.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.64.
Check Avidity Biosciences Probability Of Bankruptcy
Ownership AllocationThe majority of Avidity Biosciences outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Avidity Biosciences to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Avidity Biosciences. Please pay attention to any change in the institutional holdings of Avidity Biosciences as this could imply that something significant has changed or is about to change at the company.
Check Avidity Ownership Details
Avidity Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| State Street Corp | 2024-06-30 | 3.3 M | |
| Geode Capital Management, Llc | 2024-09-30 | 2.6 M | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.5 M | |
| Casdin Capital, Llc | 2024-09-30 | 2.1 M | |
| Boxer Capital Llc | 2024-09-30 | 1.7 M | |
| Artisan Partners Limited Partnership | 2024-09-30 | 1.3 M | |
| Nuveen Asset Management, Llc | 2024-06-30 | 1.2 M | |
| Polar Capital Holdings Plc | 2024-06-30 | 1.1 M | |
| D. E. Shaw & Co Lp | 2024-09-30 | 1.1 M | |
| Fmr Inc | 2024-09-30 | 16.8 M | |
| T. Rowe Price Associates, Inc. | 2024-06-30 | 10.9 M |
Avidity Biosciences Historical Income Statement
Avidity Stock Against Markets
Avidity Biosciences Corporate Management
| Kathleen Gallagher | Sr Relations | Profile | |
| Teresa McCarthy | Chief Officer | Profile | |
| Eric Mosbrooker | Chief Officer | Profile | |
| III JD | Consultant | Profile | |
| Michael CPA | Chief Officer | Profile | |
| Michael MacLean | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Avidity Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Avidity Stock refer to our How to Trade Avidity Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avidity Biosciences. If investors know Avidity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avidity Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.88) | Revenue Per Share 0.103 | Quarterly Revenue Growth (0.17) | Return On Assets (0.18) | Return On Equity (0.28) |
The market value of Avidity Biosciences is measured differently than its book value, which is the value of Avidity that is recorded on the company's balance sheet. Investors also form their own opinion of Avidity Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Avidity Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avidity Biosciences' market value can be influenced by many factors that don't directly affect Avidity Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avidity Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avidity Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avidity Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.